Montag A & Associates Inc. Has $11.03 Million Stock Position in Stryker Corporation $SYK

Montag A & Associates Inc. boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 5.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 34,949 shares of the medical technology company’s stock after acquiring an additional 1,837 shares during the quarter. Montag A & Associates Inc.’s holdings in Stryker were worth $11,034,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of SYK. Vanguard Group Inc. grew its stake in shares of Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after purchasing an additional 133,892 shares during the last quarter. State Street Corp raised its position in Stryker by 2.1% in the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after purchasing an additional 311,507 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after buying an additional 69,851 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after buying an additional 1,198,665 shares in the last quarter. Finally, Norges Bank bought a new position in Stryker in the 4th quarter valued at $1,822,272,000. 77.09% of the stock is owned by institutional investors.

Stryker Trading Down 0.7%

SYK opened at $338.80 on Friday. The stock has a market capitalization of $129.95 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.16 and a beta of 0.76. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The firm’s fifty day simple moving average is $324.61 and its 200 day simple moving average is $333.57. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the prior year, the business earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, research analysts anticipate that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

Analyst Upgrades and Downgrades

SYK has been the subject of several research reports. Leerink Partners lowered their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Raymond James Financial set a $370.00 price target on Stryker in a report on Friday, July 31st. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. BMO Capital Markets initiated coverage on Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective for the company. Finally, Piper Sandler cut their target price on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $386.28.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.